November, 2022Bright Peak Presents New Therapeutics Highlighted by Multifunctional PD-1 Targeted Immunocytokines at SITC 2022Read MoreOctober, 2022Bright Peak Therapeutics to Present Innovative Best-in-Class and Multifunctional Regulatory T Cell (Treg) Enhancers at the 10th International Conference on Autoimmunity: Mechanisms and Novel TreatmentsRead MoreOctober, 2022Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory BoardRead MoreAugust, 2022Bright Peak Therapeutics Announces the Appointment of Cancer Immunotherapy Leader Jon Wigginton, M.D., as President of Research and Development Read MoreMarch, 2022Bright Peak Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual MeetingRead MoreFebruary, 2022Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to its Board of DirectorsRead MoreNovember, 2021Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of DirectorsRead MoreNovember, 2021Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted ImmunocytokinesRead MoreJune, 2021Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of DirectorsRead MoreMarch, 2021Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel ImmunocytokinesRead MoreApril, 2020Versant Ventures Launches Bright Peak TherapeuticsRead More
'